PAC-MAN

ORGANIZATION

Scientists

Dr. Ennio Tasciotti

PhD

Prof. Tasciotti is a pioneer in the development of biomimetic nanotechnologies for biomedical applications in the field of drug delivery with a solid expertise in coordinating highly interdisciplinary collaborative research groups in the context of large multi-center scientific programs with leading institutions (Harvard, MIT, Stanford, Northwestern, MD Anderson Cancer Center, Italian Ministry of Health, etc).

  1. Multifunctional Nanostructured Platform for Localized Sustained Release of Analgesics.” Murphy, M., Khaled, S., Fan, D., Yazdi, I., Buchanan, R., Smid, C., Weiner, B., Ferrari, M., Tasciotti, E. European Journal of Pain. 2011; 5(2):423-32.
  2. Nanomedicine: Ushering a new era of pain management.” Sprintz, M., Tasciotti, E., Allegri, M., Grattoni, A., Driver, L., Ferrari, M. European Journal of Pain. 2011; 5(2):317-22.
  3. Nanostructered lidocaine delivery system decreases postsurgical pain in Lewis rats” J L. Van Eps, J S. Fernandez-Moure, Z K. Menn, I K. Yazdi, Sm Z. Khaled, B.K.Weiner, B.Bass, E. Tasciotti. Journal of the American College of Surgeons, Volume 217, Issue 3, Pages S139-S140, September 2013
  4. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell- like functions”.Parodi, A., Quattrocchi, N., Van de Ven, A., Chiappini, C., Evangelopoulos, M., Martinez, J., Brown, B., Khaled, S., Yazdi, I., Victoria Enzo, M., Isenhart, L., Ferrari, M., Tasciotti, E. Nature Nanotechnology. 2013 Jan; 8(1):61–8. (Cover Story).
  5. Biomimetic proteolipid vesicles for targeting inflamed tissues.” R. Molinaro, C. Corbo, J. O. Martinez, F. Taraballi, M. Evangelopoulos, S. Minardi, E. De Rosa, I.K. Yazdi, P. Zhao, M.B. Sherman, A. De Vita, N.E. Toledano Furman, X. Wang, A. Parodi, E. Tasciotti. Nature Materials. 2016  May. doi.org/10.1038/nmat4644

Affiliation: IRCCS San Raffaele (Italy)
E-mail: ennio.tasciotti@sanraffaele.it

Dr. Marina Lusic

PhD

Dr Marina Lusic, PhD is a genome biologist with a long experience in studying epigenetic and genomic changes related to viral infections and identifying potentially druggable molecular pathways that restrict viral infections.  Her team has proposed new drug targets for treatment of HIV-1 and most recently for SARS-CoV2 infection.

  1. The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication in vitro and decreases viral titers and disease progression in Syrian hamsters. Shytaj IL, Fares M, Lucic B, Galluci L, Tolba M, Zimmermann L, Ayoub AT, Cortese M, Neufeldt CJ, Laketa V, Chlanda P, Fackler OT, Boulant S, Bartenschlager R, Stanifer M, Savarino A, Lusic M. mBio 2022 Mar 1:13(2). (IF: 6.784) (Cite Score:11.2)
  2. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitized infected cells to oxidative stress. Shytaj IL, Procopio FA, Tarek M, Carlon -Andres I, Tang H-Y, Goldman, AR, Munshi, M H, Forcato M, Leskov K, Ye F, Lucic B, Cruz N, Singh A, Bicciato S, Padilla-Parra S, Diaz RS,  Lusic M, Karn J, Alvarez-Carbonell D, Savarino A. EMBO Mol Med. 2021 Aug 9;13(8):e13901(IF: 10,29) (Cite Score:16.2)
  3. Alterations of redox and iron metabolism accompany development of HIV latency. Shytaj IL, Lucic B, Forcato M, Penzo, C, Billingsley J, Laketa, V, Bosinger S, Stanic M, Gregoretti F, Antonelli L, Oliva G, Frese K, Trifunovic A, Galy B, Eibl C, Silvestri G, Bicciato S, Savarino A and Lusic M. EMBO J 2020 May 4, 39(9) (IF:11.6) (Cite Score:17.8)
  4. Spatially clustered loci with multiple enhancers are frequent targets of HIV-1 Lucic B, Chen H-C, Kuzman M, Zorita E,, Wegner J, Minneker V, Wang W, FronzaR, Laufs S, Schmidt M, Stadhouders R, Roukos V,  Vlahovicek K, Filion GJ and Lusic M. Nature Commun 2019 Sept; 10(1):4059 (IF:17.61)(Cite Score:23.2)
  5. Nuclear architecture dictates HIV-1 integration site selection Marini B, Kertesz-Farkas A, Lucic B, Hashim A, Lisek K, Manganaro L, Pongor S, Luzzati R, Mavilio F, Giacca M and Lusic M (2015). Nature 14; 521 (7551): 227-31, Epub 2015 Mar 2) (IF 69.504)( Cite Score:70.2)

Affiliation: Heidelberg University Hospital (Germany)
E-mail: Marina.lusic@med.uni-heidelberg.de

Dr. Luda Diatchenko

MD, PhD

Prof. Diatchenko has made seminal contributions to the field of human pain genetics identifying the pathophysiology of chronic pain, genetic markers for accurate diagnosis, and potential therapeutic targets. She pioneered a reverse genetic approach in pain using human samples rather than animal models as a starting point for discoveries.

  1. Brain-specific genes contribute to chronic but not to acute back pain. Bortsov AV, Parisien M, Khoury S, Martinsen AE, Lie MU, Heuch I, Hveem K, Zwart JA, Winsvold BS, Diatchenko L. Pain Rep. 2022 Aug 9;7(5):e1018.
  2. Omics approaches to discover pathophysiological pathways contributing to human pain. Diatchenko L, Parisien M, Jahangiri Esfahani S, Mogil JS. Pain. 2022 Nov 1;163(Suppl 1):S69-S78.
  3. Optimizing and Accelerating the Development of Precision Pain Treatments for Chronic Pain: IMMPACT Review and Recommendations. Edwards RR, Schreiber KL, Dworkin RH, Turk DC, Baron R, Freeman R, Jensen TS, Latremoliere A, Markman JD, Rice ASC, Rowbotham M, Staud R, Tate S, Woolf CJ, Andrews NA, Carr DB, Colloca L, Cosma-Roman D, Cowan P, Diatchenko L, Farrar J, Gewandter JS, Gilron I, Kerns RD, Marchand S, Niebler G, Patel KV, Simon LS, Tockarshewsky T, Vanhove GF, Vardeh D, Walco GA, Wasan AD, Wesselmann U. J Pain. 2022 Oct 2:S1526- 5900(22)00415-1.
  4. Acute inflammatory response via neutrophil activation protects against the development of chronic pain. Parisien M, Lima LV, Dagostino C, El-Hachem N, Drury GL, Grant AV, Huising J, Verma V, Meloto CB, Silva JR, Dutra GGS, Markova T, Dang H, Tessier PA, Slade GD, Nackley AG, Ghasemlou N, Mogil JS, Allegri M, Diatchenko L. Sci Transl Med. 2022 May 11;14(644):eabj9954.
  5. Identifying genetic determinants of inflammatory pain in mice using a large-scale gene- targeted screen. Wotton JM, Peterson E, Flenniken AM, Bains RS, Veeraragavan S, Bower LR, Bubier JA, Parisien M, Bezginov A, Haselimashhadi H, Mason J, Moore MA, Stewart ME, Clary DA, Delbarre DJ, Anderson LC, D’Souza A, Goodwin LO, Harrison ME, Huang Z, Mckay M, Qu D, Santos L, Srinivasan S, , Chesler EJ, Smedley D, Diatchenko L, Baumbauer KM, Young EE, Bonin RP, Mandillo S, White JK; International Mouse Phenotyping Consortium. Pain. 2022 Jun 1;163(6):1139-1157.

Affiliation: McGill University (Canada)
E-mail: luda.diatchenko@mcgill.ca

Dr. Assaf Zinger

PhD

Dr. Assaf Zinger is a Biomedical Engineer with vast experience in developing nanodelivery systems combining biomedical and chemical engineering with pharmacology. He holds two academic affiliations both at Technion-Israel Institute of Technology and Houston Methodist Academic Institute, TX, USA.

  1. Humanized Biomimetic Nanovesicles for Neuron Targeting. Zinger, A., Cvetkovic, C., Sushnitha, M., Naoi, T., Baudo, G., Anderson, M., Shetty, A., Basu, N., Covello, J. & Tasciotti, E. Advanced Science, 2101437 (2021). It was chosen as the journal supplementary cover. Relevance to this proposal: It illustrates my capacity to mimic innate cellular mechanisms (i.e., neuron-to-neuron cellular adhesion) using biomimetic nanoparticles.
  2. Biomimetic nanoparticles as a theranostic tool for traumatic brain injury.  Zinger, A., Soriano, S., Baudo, G., De Rosa, E., Taraballi, F. & Villapol, S. Advanced Functional Materials, 2100722 (2021). Relevance to this proposal: It illustrates my capacity to use biomimetic nanoparticles in complex in vivo models while imaging and assessing them using intravital microscope.
  3. Enhancing inflammation targeting using tunable leukocyte-based biomimetic nanoparticles. Zinger, A., Sushnitha, M., Naoi, T., Baudo, G., De Rosa, E., Chang, J., Tasciotti, E. & Taraballi, F. ACS nano 15, 6326-6339 (2021). It was chosen as the journal supplementary cover. Relevance to this proposal: It illustrates my capacity to mimic another innate cellular mechanism (i.e., leukocyte-inflamed endothelia) using biomimetic nanoparticles and tuning their physiochemical properties.
  4. Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles. A. Zinger, M. Sushnitha, T. Naoi, G. Baudo, E. De Rosa, J. Chang, E. Tasciotti, F. Taraballi. ACS Nano. 2021 Apr 27;15(4):6326-6339.  doi: 10.1021/acsnano.0c05792.  Epub 2021 Mar 16. Relevance to this proposal: Our combined use of a microfluidic, bottom-up approach and tuning of a key synthesis parameter enabled the synthesis of reproducible, enhanced biomimetic nanoparticles that have the potential to improve the treatment of inflammatory-based conditions through targeted nanodelivery.
  5. Macrophage-derived nanovesicles exert intrinsic anti-inflammatory properties and prolong survival in sepsis through a direct interaction with macrophages. Molinaro R, Pastò A, Corbo C, Taraballi F, Giordano F, Martinez JO, Zhao P, Wang X, Zinger A, Boada C, Hartman KA, Tasciotti E. Nanoscale. 2019 Jul 28;11(28):13576-13586.

Affiliation: Technion – Israel Inst. of Technology (Israel)
E-mail: assafzinger@technion.ac.il

Dr. Carolina Muscoli

PhD

Prof. Muscoli has a long experience in understanding the molecular mechanisms at the basis of chronic pain and in developing innovative pharmaceutical and nutraceutical treatments for acute and chronic pain from the animal models to human trials.

  1. Tantali Fibromyalgic Supplicium: Is There Any Relief With the Antidepressant Employment? A Systematic Review. Ilari S, Passacatini LC, Malafoglia V, Oppedisano F, Maiuolo J, Gliozzi M, Palma E, Tomino C, Fini M, Raffaeli W, Mollace V, Muscoli C. Pharmacol Res. 2022 Nov 3:106547. A systematic review with a profound analysis of the patients pain conditions and the unmet needs.
  2. The Protective Effect of Bergamot Polyphenolic Fraction (BPF) on Chemotherapy-Induced Neuropathic Pain. Ilari S, Lauro F, Giancotti LA, Malafoglia V, Dagostino C, Gliozzi M, Condemi A, Maiuolo J, Oppedisano F, Palma E, Tomino C, Salvemini D, Mollace V, Muscoli C. Pharmaceuticals (Basel). 2021. Sep 25;14(10):975. This study showed that the use of nutraceuticals improved paclitaxel-induced pain behaviors relieving the development of chemotherapy-induced neuropathic pain.
  3. Natural Antioxidant Control of Neuropathic Pain-Exploring the Role of Mitochondrial SIRT3 Pathway. Ilari S, Giancotti LA, Lauro F, Gliozzi M, Malafoglia V, Palma E, Tafani M, Russo MA, Tomino C, Fini M, Salvemini D, Mollace V, Muscoli C. Antioxidants (Basel). 2020 Nov 9;9(11):1103. Here we have demonstrated a close relation between oxidative stress, hyperalgesia, allodynia and sirtuins inactivation reverted by BPF (natural products) administration.
  4. Antioxidant modulation of sirtuin 3 during acute inflammatory pain: The ROS control. Ilari S, Giancotti LA, Lauro F, Dagostino C, Gliozzi M, Malafoglia V, Sansone L, Palma E, Tafani M, Russo MA, Tomino C, Fini M, Salvemini D, Mollace V, Muscoli C. Pharmacol Res. 2020. Jul;157:104851. These results suggest that therapeutic strategies aimed at inhibiting post-translational modifications of SIRT3 may provide beneficial outcomes in pain states where ROS have been documented to play an important role in the development of central sensitization.
  5. Identification of MOR-Positive B Cell as Possible Innovative Biomarker (Mu Lympho-Marker) for Chronic Pain Diagnosis in Patients with Fibromyalgia and Osteoarthritis Diseases. Raffaeli W, Malafoglia V, Bonci A, Tenti M, Ilari S, Gremigni P, Iannuccelli C, Gioia C, Di Franco M, Mollace V, Vitiello L, Tomino C, Muscoli C. Int J Mol Sci. 2020 Feb 22;21(4):1499. Here we propose the percentage of Mu-positive B cells as a biological marker for an objective diagnosis of chronic pain suffering patients, also contributing to the legitimacy of FM as a truly painful disease.

Affiliation: Università Magna Graecia (Italy)
E-mail: muscoli@unicz.it

Clinicians

Prof. Pablo Ingelmo

 

Dr. Ingelmo is a paediatric pain specialist with an extensive experience in pain children and adolescents. He has also advocated to the description of psychosocial and biological phenotypes of children with chronic primary pain.

  1. The spectrum of indomethacin-responsive headaches in children and adolescents. Myers KA, Barmherzig R, Raj NR et al. Cephalalgia. 2022 Jul;42(8):793-797.
  2. Association between Quantitative Sensory Testing and Conditioned Pain Modulation and the Prescription of Medication and Interventional Procedures in Children with Chronic Pain Conditions. Bruneau A, Ferland CE, Pérez-Medin R, et al. Children (Basel). 2022 Aug 2;9(8):1157.
  3. Canadian surveillance study of complex regional pain syndrome in children. Baerg K, Tupper SM, Chu LM, et al. Pain. 2022 Jun 1;163(6):1060-1069.
  4. Phenotyping Chronic Musculoskeletal Pain in Male and Female Adolescents: Psychosocial Profiles, Somatosensory Profiles and Pain Modulatory Profiles. Ocay DD, Larche CL, Betinjane N, et al. J Pain Res. 2022 Feb 26;15:591-612.
  5. Mast cell stabilizer ketotifen fumarate reverses inflammatory but not neuropathic-induced mechanical pain in mice. Meloto CB, Ingelmo P, Perez EV, et al. Pain Rep. 2021 Jun 3;6(2):e902.

Affiliation: Montreal Childrens Hospital (Canada)
E-mail: pablo.ingelmo@mcgill.ca

Prof. Sam Eldabe

MD

Prof. Eldabe is one of the most important researchers in the development of new treatments for chronic pain, especially in neuromodulation, collaborating in several clinical studies. He is currently involved in a European study about long COVID and pain

  1. Does a Screening Trial for Spinal Cord Stimulation in Patients With Chronic Pain of Neuropathic Origin Have Clinical Utility (TRIAL-STIM)? 36-Month Results From a Randomized Controlled Trial. Eldabe S, Nevitt S, Griffiths S, Gulve A, Thomson S, Baranidharan G, Houten R, Brookes M, Kansal A, Earle J, Bell J, Taylor RS, Duarte RV. Neurosurgery. 2022 Oct 13.  doi: 10.1227/neu.0000000000002165
  2. Systematic Review to Identify Predictors of Treatment Response to Neuromodulation in Patients With Neuropathic Pain. Kansal A, Duarte R, Copley S, Warren FC, Taylor RS, Eldabe S. Protocol. Neuromodulation: Technology at the Neural Interface 2022. 10.1016/j.neurom.2022.07.010
  3. A prospective long-term follow-up of dorsal root ganglion stimulation for the management of chronic intractable pain. Eldabe S, Copley S, Gulve A, Baranidharan G, Bretherton B, Kansal A, Madzinga G, Brookes M, Thomson S, Duarte RV. Pain 163(4):702-710, April 2022.
  4. Development and testing of an opioid tapering self-management intervention for chronic pain: I-WOTCH. Sandhu HK, Shaw J, Carnes D, Furlan AD, Tysall C, Adjei H, Muthiah C, Noyes J, Tang NKY, Taylor SJC, Underwood M, Willis A, Eldabe S. BMJ open 2022;12(3).
  5. Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel. Shanthanna H, Strand NH, Provenzano DA, Lobo CA, Eldabe S, et al. Anaesthesia 2020;75(7):935-944.

Affiliation: The James Cook University Hospital, Hospitals NHS Foundation Trust (UK)
E-mail: seldabe@nhs.net

Prof. Gisele Pickering

MD, PhD

Prof. Gisele Pickering basic research concerns the mechanisms of action of analgesics, including NMDA antagonists for severe chronic pain, while her clinical research includes over 30 trials/year on pain research.

  1. Ketamine for refractory chronic pain: a 1-year follow-up study. OKAPI Consortium. Corriger A, Voute M, Lambert C, Pereira B, Pickering G; Pain. 2022 Apr 1;163(4):690-701. doi: 10.1097/j.pain.0000000000002403. PMID: 34252909
  2. When pain science and practice meet policies. Why do we need to implement the ICD-11? Barke A, Cano Palomares A, Cameron P, Forget P, Ryan D, Vanhaute O, Wilkinson J. Eur J Pain. 2022 Oct;26(9):2003-2005. doi: 10.1002/ejp.2015. Epub 2022 Aug 12. McSwan J, Gudin J, Song XJ, Grinberg Plapler P, Betteridge NJ, Kechemir H, Igracki-Turudic I, Pickering G.
  3. Self-Healing: A Concept for Musculoskeletal Body Pain Management – Scientific Evidence and Mode of Action. J Pain Res. 2021 Sep 21;14:2943-2958. doi: 10.2147/JPR.S321037. eCollection 2021. PMID: 34584448
  4. Phenotyping Post-COVID Pain as a Nociceptive, Neuropathic, or Nociplastic Pain Condition Biomedicines. Fernández-de-Las-Peñas C, Nijs J, Neblett R, Polli A, Moens M, Goudman L, Shekhar Patil M, Knaggs RD, Pickering G, Arendt-Nielsen L. 2022 Oct 13;10(10):2562. doi: 10.3390/biomedicines10102562. PMID: 36289827 
  5. Short-Term Magnesium Therapy Alleviates Moderate Stress in Patients with Fibromyalgia: A Randomized Double-Blind Clinical Trial. Macian N, Dualé C, Voute M, Leray V, Courrent M, Bodé P, Giron F, Sonneville S, Bernard L, Joanny F, Menard K, Ducheix G, Pereira B, Pickering G. Nutrients. 2022 May 17;14(10):2088. doi: 10.3390/nu14102088.PMID: 35631229

Affiliation: University Hospital of Clermont-Ferrand (France)
E-mail: gisele.pickering@uca.fr

Prof. Thomas Volk

 

Prof. Volk is chair and head of the university pain clinic. He is the president of the European Society on Regional Anesthesia and Pain Medicine.

  1. Postoperative Pain Therapy with Laser Acupuncture after Cesarean Section under Spinal Anesthesia: A Double-Blinded, Randomized, Placebo-Controlled Trial. Brase A, Brauchle D, Kermad A, Volk T, Morinello E, Gottschling S, Schneider SO. Complement Med Res. 2022;29(3):235-241
  2. Antithrombotic drugs and the risk of bloody punctures in regional anesthesia – a retrospective registry analysis. Kubulus C, Gürtesch CA, Wagenpfeil G, Sessler DI, Volk T. Reg Anesth Pain Med. 2022 Aug 3:rapm-2022-103806
  3. Sedaconda study group. Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial. Meiser A, Volk T, Wallenborn J, Guenther U, Becher T, Bracht H, Schwarzkopf K, Knafelj R, Faltlhauser A, Thal SC, Soukup J, Kellner P, Drüner M, Vogelsang H, Bellgardt M, Sackey P; Lancet Respir Med. 2021 Nov;9(11):1231-1240
  4. Big Data in Studying Acute Pain and Regional Anesthesia. Müller-Wirtz LM, Volk T. J Clin Med. 2021 Apr 1;10(7):1425
  5. Association of Perioperative Regional Analgesia with Postoperative Patient-Reported Pain Outcomes and Opioid Requirements: Comparing 22 Different Surgical Groups in 23,911 Patients from the QUIPS Registry. Komann M, Avian A, Dreiling J, Gerbershagen H, Volk T, Weinmann C, Meißner W. J Clin Med. 2021 May 19;10(10):2194.

Affiliation: Saarland University (Germany)
E-mail: Thomas.volk@uks.eu

Prof. Dragan Primorac

MD, PhD

Prof. Dragan Primorac is a pediatrician and a medical geneticist who pioneered the understanding of the genetics of pain and the integration of the personalized medicine in clinical practice. His interest is in the use of pharmacogenomics for treatment optimization and pain management. He recently initiated one of the largest EU projects on low-back pain to understand the OMICS bases of low-back pain.

  1. Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids. Bach-Rojecky L, Vađunec D, Žunić K, Kurija J, Šipicki S, Gregg R, Mikula I, Primorac D. Personalized Medicine. 2019 Mar;16(2):171-184.
  2. Plasma N-glycome composition associates with chronic low back pain. Trbojević-Akmačić I, Vučković F, Vilaj M, Skelin A, Rauck R, Aulchenko YS, Primorac D, Kapural L, Williams FMK, van Zundert J, Allegri M, Lauc G. Biochim Biophys Acta Gen Subj. 2018 Oct;1862(10):2124-2133.
  3. Using omics in chronic pain conditions to delineate mechanisms and provide new therapeutic strategies. Freidin MB, Lauc G, Allegri M, Primorac D, Williams FM. Pain Manag. 2016;6(3):211-5.
  4. Validation of standard operating procedures in a multicenter retrospective study to identify -omics biomarkers for chronic low back pain. Dagostino C, De Gregori M, Gieger C, Manz J, Gudelj I, Lauc G, Divizia L, Wang W, Sim M, Pemberton IK, MacDougall J, Williams F, Van Zundert J, Primorac D, Aulchenko Y, Kapural L, Allegri M; PainOmics Group. PLoS One. 2017 May 1;12(5):e0176372.
  5. Composition of the immunoglobulin G glycome associates with the severity of COVID-19. Petrović T, Alves I, Bugada D, Pascual J, Vučković F, Skelin A, Gaifem J, Villar-Garcia J, Vicente MM, Fernandes Â, Dias AM, Kurolt IC, Markotić A, Primorac D, Soares A, Malheiro L, Trbojević-Akmačić I, Abreu M, Sarmento E Castro R, Bettinelli S, Callegaro A, Arosio M, Sangiorgio L, Lorini LF, Castells X, Horcajada JP, Pinho SS, Allegri M, Barrios C, Lauc G.Glycobiology. 2021 May 3;31(4):372-377.

Affiliation: St. Catherine Hospital (Croatia)
Email: office@draganprimorac.com

Dr. César Fernández-de-las-Peñas

MD

Dr. Fernandez de las Peñas is the PI of the LONG COVID EXPERIENCE Study, a European study focused on clinical, neurophysiological and epigenetics mechanisms of long-COVID, and an active researcher on the pan-European long COVID pain study. Dr. Fernández provided clinical definitions of long-COVID, and contributed to the post-COVID literature with more than 70 peer-reviewed publications.

  1. Post-COVID pain is not associated with inflammatory polymorphisms in people who had been hospitalized by COVID-19. Fernández-de-las-Peñas C, Giordano R, Díaz-Gil G, Gómez-Esquer F, Ambite-Quesada S, Palomar-Gallego MA, Arendt-Nielsen L. J Clin Med. 2022; 11 (19): 5645
  2. Are pain polymorphisms associated with the risk and phenotype of post-COVID pain in previously hospitalized COVID-19 survivors? Fernández-de-las-Peñas C, Giordano R, Díaz-Gil G, Gil-Crujera A, Gómez-Sánchez SM, Ambite-Quesada S, Arendt-Nielsen L. Genes (Basel). 2022; 13 (8): 1336. 
  3. Sensitization-associated post-COVID-19 symptoms at 6 months are not associated with serological biomarkers at hospital admission in COVID-19 survivors: A secondary analysis of a cohort study. Fernández-de-las-Peñas C, Herrero-Montes M, Ferrer-Pargada D, Izquierdo-Cuervo S, Arendt-Nielsen L, Nijs J, Parás-Bravo P. J Clin Med. 2022; 11 (12): 3512. 
  4. Prevalence and risk factors of musculoskeletal pain symptoms as long-term post-COVID sequelae in hospitalized COVID- 19 survivors: a multicenter study. Fernández-de-las-Peñas C, de-la-Llave-Rincón AI, Ortega-Santiago R, Ambite-Quesada S, Gómez-Mayordomo V, Cuadrado ML, Arias-Navalón JA, Hernández-Barrera V, Martín-Guerrero JD, Pellicer-Valero OJ, Arendt-Nielsen L. Pain. 2022; 163 (9): e989-e996. 
  5. The Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) and PainDETECT questionnaires in COVID-19 survivors with post-COVID pain. Fernández-de-las-Peñas C, Valera-Calero JA, Herrero-Montes M, Del-Valle-Loarte P, Rodríguez-Rosado R, Ferrer-Pargada D, Arendt-Nielsen L, Parás-Bravo P. Viruses. 2022; 14 (7):1486.

Affiliation: Universidad Rey Juan Carlos (Spain)
E-mail: cesar.fernandez@urjc.es

Prof. Jean-Pierre Van Buyten

MD

Dr. Jean-Pierre Van Buyten MD, PhD. is currently the Chairman of The Multidisciplinary Pain Management Center in AZ Nikolaas Hospital in Sint-Niklaas Belgium and Consultant in Pain Medicine in Delta Hospital Brussels Belgium.

  1. Three-Year Durability of Restorative Neurostimulation Effectiveness in Patients With Chronic Low Back Pain and Multifidus Muscle Dysfunction. Gilligan C, Volschenk W, Russo M, Green M, Gilmore C, Mehta V, Deckers K, De Smedt K, Latif U, Sayed D, Georgius P, Gentile J, Mitchell B, Langhorst M, Huygen F, Baranidharan G, Patel V, Mironer E, Ross E, Carayannopoulos A, Hayek S, Gulve A, Van Buyten JP, Tohmeh A, Fischgrund J, Lad S, Ahadian F, Deer T, Klemme W, Rauck R, Rathmell J, Schwab F, Maislin G, Heemels JP, Eldabe S.Neuromodulation. 2022 Sep 26:S1094-7159(22)01254-5
  2. Spinal Cord Stimulation-Naïve Patients vs Patients With Failed Previous Experiences With Standard Spinal Cord Stimulation: Two Distinct Entities or One Population? Goudman L, Rigoard P, Billot M, De Smedt A, Roulaud M, Consortium D, Moens M; Discover Consortium.Neuromodulation. 2022 May 9:S1094-7159(22)00640-7.
  3. Long-term quality of life and work status after high-dose spinal cord stimulation in patients with failed back surgery syndrome: a secondary analysis of real-world data. Goudman L, De Smedt A, Putman K, Moens M; Discover Consortium.J Neurosurg Spine. 2020 Dec 18;34(3):440-448
  4. Optimizing the Management and Outcomes of Failed Back Surgery Syndrome: A Proposal of a Standardized Multidisciplinary Team Care Pathway. Gatzinsky K, Eldabe S, Deneuville JP, Duyvendak W, Naiditch N, Van Buyten JP, Rigoard P. Pain Res Manag. 2019 Jul 8;2019:8184592.

Affiliation: Multidisciplinary Pain Center. Vitaz hospital. Sint – Niklaas (Belgium)
E-mail: info@drvanbuyten.be

Prof. Lars Arendt-Nielsen

MD

Prof Arendt-Nielsen, ex past president of International Association of Pain he is one of the most contributors in studies about the evaluating of central sensitization and how acute pain can become chronic.

  1. Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study. Fernández-de-Las-Peñas C, Rodríguez-Jiménez J, Fuensalida-Novo S, Palacios-Ceña M, Gómez-Mayordomo V, Florencio LL, Hernández-Barrera V, Arendt-Nielsen L. Pain. 2021 Dec 1;162(12):2832-2840.
  2. Phenotyping Post-COVID Pain as a Nociceptive, Neuropathic, or Nociplastic Pain Condition. Fernández-de-Las-Peñas C, Nijs J, Neblett R, Polli A, Moens M, Goudman L, Shekhar Patil M, Knaggs RD, Pickering G, Arendt-Nielsen L. Biomedicines. 2022 Oct 13;10(10):2562.
  3. Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis. Fernández-de-Las-Peñas C, Navarro-Santana M, Plaza-Manzano G, Palacios-Ceña D, Arendt-Nielsen L. Pain. 2022 Jul 1;163(7):1220-1231.
  4. Serological biomarkers of COVID-19 severity at hospital admission are not related to long-term post-COVID pain symptoms in hospitalized COVID-19 survivors. Fernández-de-Las-Peñas C, Ryan-Murua P, de-la-Llave-Rincón AI, Gómez-Mayordomo V, Arendt-Nielsen L, Torres-Macho J. Pain. 2022 Nov 1;163(11):2112-2117.
  5. A year like no other: introduction to a special issue on COVID-19 and pain. Rowbotham MC, Arendt-Nielsen L. Pain Rep. 2021 May 10;6(1):e915.

Affiliation: Aalborg University and Aalborg University Hospital (Denmark)
E-mail: lan@hst.aa.dk

Dr. Massimo Allegri

MD, PhD

Dr. Massimo Allegri is a clinician with clinical and research experience in chronic pain with a special focus on translational medicine and the clinical use of genomics to better understand acute and chronic pain. He serves as Pi of a European Study on genomics and pain and he is an active researcher on the pan-European long COVID pain study.

  1. Acute inflammatory response via neutrophil activation protects against the development of chronic pain. Parisien M, Lima LV, Dagostino C, El-Hachem N, Drury GL, Grant AV, Huising J, Verma V, Meloto CB, Silva JR, Dutra GGS, Markova T, Dang H, Tessier PA, Slade GD, Nackley AG, Ghasemlou N, Mogil JS, Allegri M, Diatchenko L.Sci Transl Med. 2022 May 11;14(644):eabj9954.
  2. Non-drug pain relievers active on non-opioid pain mechanisms. Marchesi N, Govoni S, Allegri M.Pain Pract. 2022 Feb;22(2):255-275
  3. Effects of Environmental Factors on Severity and Mortality of COVID-19. Kifer D, Bugada D, Villar-Garcia J, Gudelj I, Menni C, Sudre C, Vučković F, Ugrina I, Lorini LF, Posso M, Bettinelli S, Ughi N, Maloberti A, Epis O, Giannattasio C, Rossetti C, Kalogjera L, Peršec J, Ollivere L, Ollivere BJ, Yan H, Cai T, Aithal GP, Steves CJ, Kantele A, Kajova M, Vapalahti O, Sajantila A, Wojtowicz R, Wierzba W, Krol Z, Zaczynski A, Zycinska K, Postula M, Lukšić I, Čivljak R, Markotić A, Brachmann J, Markl A, Mahnkopf C, Murray B, Ourselin S, Valdes AM, Horcajada JP, Castells X, Pascual J, Allegri M, Primorac D, Spector TD, Barrios C, Lauc G.Front Med (Lausanne). 2021 Jan 20;7:607786.
  4. Composition of the immunoglobulin G glycome associates with the severity of COVID-19. Petrović T, Alves I, Bugada D, Pascual J, Vučković F, Skelin A, Gaifem J, Villar-Garcia J, Vicente MM, Fernandes Â, Dias AM, Kurolt IC, Markotić A, Primorac D, Soares A, Malheiro L, Trbojević-Akmačić I, Abreu M, Sarmento E Castro R, Bettinelli S, Callegaro A, Arosio M, Sangiorgio L, Lorini LF, Castells X, Horcajada JP, Pinho SS, Allegri M, Barrios C, Lauc G.Glycobiology. 2021 May 3;31(4):372-377.

Affiliation: Ensemble Hospitalier de la Cote – Centre Lemanique d’antalgie et neuromodulation (Switzerland)
E-Mail: massimo.allegri@ehc.vd.ch

Companies

Dr. Gordan Lauc

MD

Dr Lauc with his company is providing new important diagnostic and pathophysiologic insights in chronic inflammatory diseases through the glycomics studies. He has already performed some studies about glycomics as a possible biomarker in Covid, and also marker of pain.

  1. Differences in Immunoglobulin G Glycosylation Between Influenza and COVID-19 Patients. Kljaković-Gašpić Batinjan M, Petrović T, Vučković F, Hadžibegović I, Radovani B, Jurin I, Đerek L, Huljev E, Markotić A, Lukšić I, Trbojević-Akmačić I, Lauc G, Gudelj I, Čivljak R.Engineering (Beijing). 2022 Sep 6.
  2. IgG N-glycome changes during the course of severe COVID-19: An observational study. Petrović T, Vijay A, Vučković F, Trbojević-Akmačić I, Ollivere BJ, Marjanović D, Bego T, Prnjavorac B, Đerek L, Markotić A, Lukšić I, Jurin I, Valdes AM, Hadžibegović I, Lauc G. EBioMedicine. 2022 Jul;81:104101.
  3. Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity. Vicente MM, Alves I, Gaifem J, Rodrigues CS, Fernandes Â, Dias AM, Štambuk J, Petrović T, Oliveira P, Ferreira-da-Silva F, Soares A, Seixas N, Teixeira T, Malheiro L, Abreu MM, Lauc G, Sarmento E Castro R, Pinho SS. Eur J Immunol. 2022 Jun;52(6):946-957.
  4. SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection. Trbojević-Akmačić I, Petrović T, Lauc G. Glycoconj J. 2021 Oct;38(5):611-623
  5. The Importance of Glycosylation in COVID-19 Infection. Petrović T, Lauc G, Trbojević-Akmačić I. Adv Exp Med Biol. 2021;1325:239-264
  6. Effects of Environmental Factors on Severity and Mortality of COVID-19. Kifer D, Bugada D, Villar-Garcia J, Gudelj I, Menni C, Sudre C, Vučković F, Ugrina I, Lorini LF, Posso M, Allegri M, Primorac D, Spector TD, Barrios C, Lauc G. Front Med (Lausanne). 2021 Jan 20;7:607786.

Affiliation: Genos Ltd (Canada)
E-mail: glauc@genos.hr

Dr. Filippo Sertorio

 

Dr. Sertorio has been the president of Procemsa, one of the leading CDMO in Europe with experience in phytopharma, food supplements, and therapeutics formulations with several patents in the field of natural products, delivery platforms, and production processes. Dr. Sertorio is an expert in developing strategic projects and transforming ideas into concrete translational projects.

To be updated

Affiliation: Bluejays srl (Italy)
E-mail: filippo.sertorio@gmail.com

Dr. Nicoletta Marchesi

PhD

Reudyneuheart is a biotech start-up focused on new molecules and new drug targets for known molecules. Dr Marchesi interest is in neurodegenerative diseases and on the biology of ELAV proteins. She discovered new mechanism-based targets for integrators for nociplastic pain.

  1. Non-drug pain relievers active on non-opioid pain mechanisms. Marchesi N, Govoni S, Allegri M. Pain Pract. 2021;10.1111/papr.13073.  doi:10.1111/papr.13073
  2. Effect of troxerutin in counteracting hyperglycemia-induced VEGF upregulation in endothelial cells: a new option to target early stages of diabetic retinopathy? Fahmideh F, Marchesi N, Campagnoli LIM, Landini L, Caramella C, Barbieri A, Govoni S and Pascale A (2022) Front. Pharmacol. 13:951833. doi: 10.3389/fphar.2022.951833
  3. Pharmacological Versus Non-Pharmacological and Ancillary Mechanisms in Eye Drops Used in the Treatment of Glaucoma. Marchesi N, Fahmideh F, Barbieri A, Racchi M, Pascale A and Govoni S (2022) Front. Drug. Saf. Regul. 2:933471. doi: 10.3389/fdsfr.2022.933471
  4. Ocular Neurodegenerative Diseases: Interconnection between Retina and Cortical Areas. Marchesi, N.; Fahmideh, F.; Boschi, F.; Pascale, A.; Barbieri, A. Cells 2021, 10, 2394. doi: 10.3390/cells10092394
  5. Non-drug interventions in glaucoma: Putative roles for lifestyle, diet and nutritional supplements. Fahmideh F, Marchesi N, Barbieri A, Govoni S, Pascale A. Surv Ophthalmol. 2022 May- Jun;67(3):675-696.

Affiliation: REDYNEUHEART SRL (Italy)
E-mail: nicbiology86@gmail.com

Associations

Dr. Andrea Fanelli

MD

The Association REDIRECT PAIN aims to promote and share education and training programs in the field of acute and chronic perioperative pain management. 

  1. An Exploratory Pilot Study of Changes in Global DNA Methylation in Patients Undergoing Major Breast Surgery Under Opioid-Based General Anesthesia. Caputi FF, Carboni L, Rullo L, Alessandrini I, Balzani E, Melotti RM, Romualdi P, Candeletti S, Fanelli A. Front Pharmacol. 2021 Sep 21;12:733577. doi: 10.3389/fphar.2021.733577.
  2. An Explorative Study of CYP2D6’s Polymorphism in a Sample of Chronic Pain Patients. Fanelli A, Palazzo C, Balzani E, Iuvaro A, Pelotti S, Melotti RM. Pain Med. 2020 May 1;21(5):1010-1017. doi: 10.1093/pm/pnz265.
  3. Oral prolonged-release oxycodone/naloxone offers equivalent analgesia to intravenous morphine patient-controlled analgesia after knee replacement. A randomized controlled trial. Manassero A, Fanelli A, Ugues S, Bailo C, Dalmasso S. Minerva Anestesiol. 2018 Sep;84(9):1016-1023. doi: 10.23736/S0375-9393.18.12297-8.
  4. Acetaminophen or acetaminophen-codeine combinations and prescription of rescue therapy with non-steroidal anti-inflammatory drugs: a population-based study in primary care. Vannacci A, Lombardi N, Simonetti M, Fornasari D, Fanelli A, Cricelli I, Cricelli C, Lora Aprile P, Lapi F. Curr Med Res Opin. 2017 Jun;33(6):1141-1148. 
  5. Transversus Abdominis Plane Block for Postoperative Analgesia in Patients Undergoing Total Laparoscopic Hysterectomy: A Randomized, Controlled, Observer-Blinded Trial. Ghisi D, Fanelli A, Vianello F, Gardini M, Mensi G, La Colla L, Danelli G. Anesth Analg. 2016 Aug;123(2):488-92. 

Affiliation: Redirect Pain (Italy)
E-mail: info@redirectpain.it